saracatinib
Small moleculeexperimental
Saracatinib (AZD-0530) is an experimental drug being developed by AstraZeneca. It acts as a dual kinase inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor. — Wikipedia
Clinical trial activity
35 trials · 46 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
23
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00265876)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Alcohol Drinking · Phase 2
- Alcoholism · Phase 1
- Alzheimer Disease · Phase 2
- Bone Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Verrucous · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Dermatofibrosarcoma · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2/Phase 3
- Fibrosarcoma · Phase 2
- Graft vs Host Disease · Phase 2
- Hamartoma · Phase 2/Phase 3
- Healthy Volunteers · Phase 1
- Idiopathic Pulmonary Fibrosis · Phase 1/Phase 2
- Leiomyosarcoma · Phase 2
- Liposarcoma · Phase 2
- Lung Neoplasms · Phase 2
- Lymphangioleiomyomatosis · Phase 2
- Melanoma · Phase 2
- Myositis Ossificans · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Neoplasms · Phase 2/Phase 3
- Pancreatic Neoplasms · Phase 2
- Parkinson Disease · Early Phase 1
- Pleural Effusion, Malignant · Phase 2
- Prostatic Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Endometrial Stromal · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thymoma · Phase 2
- Tongue Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Tyrosine-protein kinase SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1- Mol. weight
- 542.04 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSaracatinib ↗
- ChEMBLCHEMBL217092 ↗
Also known as
- 4-quinazolinamine, n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1- piperazinyl)ethoxy)-5-((tetrahydro-2h-pyran-4-yl)oxy)-
- az-10353926
- az-10353926
- azd0530
- azd0530
- azd0530
- azd 0530
- azd-0530
- azd-0530
- azd-0530
- azd0530 difumarate
- n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methyl-1-piperazinyl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)-4-quinazolinamine
- n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2h-pyran-4-yloxy)quinazolin-4-amine
- n-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-((tetrahydro- 2h-pyran-4-yl)oxy)quinazolin-4-amine bi((2e)-but-2-enedioate)
- saracatinib
- saracatinib
- saracatinib
- saracatinib
- saracatinib
- saracatinib difumerate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04598919 | Phase 1/Phase 2 (Phase 2) | Nov 12, 2020 | AstraZeneca, Icahn School of Medicine at Mount Sinai, National Center for Advancing Translational Science (NCATS), University of Colorado, Denver, Yale University |
| NCT04307953 | Phase 2 | Mar 13, 2020 | AstraZeneca, European Commission, Free University of Amsterdam, Harvard University, Klinikum Garmisch-Patenkirchen, Royal National Orthopaedic Hospital NHS Trust, University of Amsterdam, University of Oxford |
| NCT03661125 | Early Phase 1 (Phase 1) | Dec 1, 2018 | AstraZeneca, University of London |
| NCT02955186 | Phase 2 | May 9, 2017 | Yale University |
| NCT02737202 | Phase 2 | Apr 1, 2016 | Baylor University, Ben Taub Hospital, Harvard University, Loyola University, National Institutes of Health (NIH), Stanford University, University of Cincinnati, University of South Florida |
| NCT02732587 | Phase 1 | Nov 1, 2015 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University |
| NCT02167256 | Phase 2 | Dec 1, 2014 | Alzheimer's Therapeutic Research Institute, University of Southern California, Yale University |
| NCT02262026 | Phase 1 | Nov 1, 2014 | Yale University |
| NCT02116712 | Phase 1 | Aug 1, 2014 | Baylor University, The University of Texas, Dallas, University of Cincinnati, University of Texas at Houston |
| NCT02085603 | Phase 2 | Mar 1, 2014 | AstraZeneca, Sheffield Hallam University |
| NCT01864655 | Phase 1 | Jul 1, 2013 | Yale University |
| NCT01196741 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2011 | AstraZeneca, Cancer Research UK, University of London |
| NCT01267266 | Phase 2 | Dec 1, 2010 | National Cancer Institute (NCI), University of Chicago |
| NCT01000896 | Phase 1 | Jan 1, 2010 | AstraZeneca, National Hospital Organisation Kyushu Cancer Centre, National Hospital Organisation Shikoku Cancer Centre |
| NCT00752206 | Phase 2 | Mar 1, 2009 | AstraZeneca, National Institutes of Health (NIH), Sarcoma Alliance for Research through Collaboration |
| NCT00853983 | Phase 1 | Mar 1, 2009 | AstraZeneca |
| NCT00771979 | Phase 1 | Nov 1, 2008 | AstraZeneca |
| NCT01216176 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2008 | Stanford University, University of Miami |
| NCT00735917 | Phase 2 | Oct 1, 2008 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00718809 | Phase 2 | Jun 1, 2008 | Indiana University, National Cancer Institute (NCI) |
Showing 20 of 35 trials
Page 1 / 2
Organizations
Research & Development (46)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 14 | 8 | 3 | 2007 |
| National Cancer Institute (NCI) | Government | 12 | 12 | 1 | 2006 |
| Yale University | Academic/Hospital | 6 | 5 | 2 | 2013 |
| University of Toronto | Academic/Hospital | 4 | 0 | 1 | 2005 |
| Baylor University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Cornell University | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2009 |
| Stanford University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| University of Chicago | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Cincinnati | Academic/Hospital | 2 | 0 | 2 | 2014 |
| University of London | Academic/Hospital | 2 | 2 | 2 | 2011 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 2 | 2006 |
| Alzheimer's Therapeutic Research Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Ben Taub Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2011 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| European Commission | Government | 1 | 0 | 1 | 2020 |
46 organizations
Page 1 / 3